While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. Gene therapy has recently emerged as a novel strategy to treat heart failure. Our group has recently completed a First-in-Man Phase 1 and Phase 2 trials targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) using adenoassociated vector type 1 AAV1.SERCA2a. Even though AAV vectors have been proven to be safe in this trial, they have been found not to be specific for the heart and pre-existence neutralizing antibodies result in the exclusion of a large percentage of the patients. We have developed novel cardiotropic chimerics of AAV (which are also known as Bio Nano Particles (BNP) that more specifically target the heart and escape the inherent immunity in patients. In STAGE 1 of this proposal: 1) we have developed and characterized a novel BNP vector (BNP116) which has high cardiotropism while de-targeting the liver, lungs, kidneys and brain, 2) we have shown that it has higher resistance to antecedent human neutralizing antibodies (thereby allowing more patients to be included), 3) we have shown that BNP116 carrying the constitutively active form of protein phosphatase inhibitor 1 (l1c) is effective in reversing contractile dysfunction in a porcine model of HF, and 4) we have completed a pre-IND meeting with the FDA and we have agreed on a path forward for the final toxicology studies. In the current stage 2 proposal, Dr. Deborah Ascheim will be the Joint-PI. She is the Clinical Director of Research and Director of the Clinical Research Unit at the International Center for Health Outcomes &Innovation Research (InCHOIR) at Mount Sinai. She and her team at InCHOIR have significant expertise in the design, conduct and analysis of multi-center trials, including the use of composite endpoints, facilitating timely enrollment and reducing site-specific barriers to recruitment. We will carry ou a phase 1, Open-Labeled, Dose-Escalation Trial of BNP116.CMV.l1c followed by a Phase 2, Randomized, Double-Blinded Placebo-Controlled Dose Escalation Trial of Intra-Coronary Infusion of BNP116.CMV.l1c in Patients with Heart Failure.

Public Health Relevance

Congestive heart failure is a major cause of morbidity and mortality in the US, and there is a critical need to explore new therapeutic approaches. Recent advances in understanding of the molecular basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology, have placed heart failure within reach of gene-based therapy. In this grant, we build on our pre-clinical work in stage 1 of CTRIP to propose Phase 1 and Phase 2 clinical trials in gene therapy using novel vectors and a novel gene target for the treatment of heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL112324-02
Application #
8463865
Study Section
Special Emphasis Panel (ZHL1-CSR-H (F1))
Program Officer
Shah, Monica R
Project Start
2012-05-01
Project End
2017-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$2,125,769
Indirect Cost
$631,613
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Watanabe, Shin; Fish, Kenneth; Bonnet, Guillaume et al. (2018) Echocardiographic and hemodynamic assessment for predicting early clinical events in severe acute mitral regurgitation. Int J Cardiovasc Imaging 34:171-175
Hammoudi, Nadjib; Watanabe, Shin; Bikou, Olympia et al. (2018) Speckle-Tracking Echocardiographic Strain Analysis Reliably Estimates Degree of Acute LV Unloading During Mechanical LV Support by Impella. J Cardiovasc Transl Res :
Fish, Kenneth M; Ishikawa, Kiyotake; Hajjar, Roger J (2018) Stem cell therapy for acute myocardial infarction: on the horizon or still a dream? Coron Artery Dis 29:89-91
Ishikawa, Kiyotake; Watanabe, Shin; Lee, Philyoung et al. (2018) Acute Left Ventricular Unloading Reduces Atrial Stretch and Inhibits Atrial Arrhythmias. J Am Coll Cardiol 72:738-750
Oh, Jae Gyun; Watanabe, Shin; Lee, Ahyoung et al. (2018) miR-146a Suppresses SUMO1 Expression and Induces Cardiac Dysfunction in Maladaptive Hypertrophy. Circ Res 123:673-685
Jeong, Dongtak; Yoo, Jimeen; Lee, Philyoung et al. (2018) miR-25 Tough Decoy Enhances Cardiac Function in Heart Failure. Mol Ther 26:718-729
Stillitano, Francesca; Karakikes, Ioannis; Hajjar, Roger J (2017) Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells. Methods Mol Biol 1521:183-193
Watanabe, Shin; Leonardson, Lauren; Hajjar, Roger J et al. (2017) Cardiac Gene Delivery in Large Animal Models: Antegrade Techniques. Methods Mol Biol 1521:227-235
Guénantin, Anne-Claire; Briand, Nolwenn; Capel, Emilie et al. (2017) Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. Diabetes 66:1470-1478
Yoo, Jimeen; Hajjar, Roger J; Jeong, Dongtak (2017) Generation of Efficient miRNA Inhibitors Using Tough Decoy Constructs. Methods Mol Biol 1521:41-53

Showing the most recent 10 out of 61 publications